Chemotherapy and radiation therapy remain standard for locally advanced and metastatic cervical cancer. However, they often ...

Photo: Esteworld Opens Its First Representative Office in the UK in London ...

During the fireside chat, Drs. Campagna and Nikodem will highlight recent corporate updates, progress on lanifibranor and the Phase III NATiV3 trial in MASH and discuss the Company’s broader R&D ...

Inventiva est une société cotée sur le compartiment B du marché réglementé d'Euronext Paris (symbole : IVA - ISIN : FR0013233012) et sur le marché Nasdaq Global Market aux Etats-Unis (symbole : IVA).

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN ), reiterates investor confidence and estimated asset value over $10 billion.

The interim report for H1 2025 is enclosed. In connection with publication of the results for H1 2025, a conference call will be hosted on 12 August 2025 at 10:00 AM CEST. The conference call will be ...

DALLAS, Aug. 11, 2025 (GLOBE NEWSWIRE) -- BHIANT, the workforce development arm of BioNTX, is charting new ground in biotechnology talent development and industry collaboration, strengthening North ...

The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observed ...

Basel, Switzerland – August 11, 2025 – FoRx Therapeutics, a clinical-stage biotechnology company developing precision anti-cancer therapeutics, today announced the dosing of the first patient in a ...

This facility is designed to provide expanded capacity and operational security as Kraig Labs scales up its recombinant spider silk manufacturing. The site will play a key role in supporting the ...

MediPharm Labs executive management team will also host a conference call and webcast on Thursday, August 14 th, 2025 at 10:00 a.m. (Eastern time) to discuss the Company’s financial results. North ...

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and developme ...